Celltrion Pharm

셀트리온제약 · 068760

Health Care Pharmaceuticals · KOSDAQ

Large-cap

Market cap US$1.5B (₩2.1T)

Overview

Celltrion Pharm makes prescription medicines, including tablets, capsules, and prefilled-syringe biologics, used to treat conditions ranging from liver disease to autoimmune disorders and cancer.

It supplies these products to patients and healthcare providers in South Korea, and its manufacturing facilities hold Korean, US, and European good-manufacturing-practice certifications. Listed on KOSDAQ, South Korea's tech and small-cap board, the company runs three distinct revenue streams: conventional chemical drugs, biologic medicines, and contract process-development services.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$388.7M

▲ +12.3% YoY

Operating profit · FY2025

US$40.6M

▲ +50.7% YoY

Net income · FY2025

US$28.1M

▲ +76.4% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$281.7M(₩388.8B)	US$346.3M(₩477.8B)	US$388.7M(₩536.4B)
Operating profit	US$26.1M(₩36.1B)	US$27M(₩37.2B)	US$40.6M(₩56.1B)
Net income	US$15.4M(₩21.3B)	US$15.9M(₩22B)	US$28.1M(₩38.8B)

Revenue

FY2023US$281.7M
FY2024US$346.3M
FY2025US$388.7M

Operating profit

FY2023US$26.1M
FY2024US$27M
FY2025US$40.6M

Net income

FY2023US$15.4M
FY2024US$15.9M
FY2025US$28.1M

Key ratios (FY2025)

ROE

8.9%

Debt/Eq

74.2%

Op. margin

10.5%

Net margin

7.2%

Rev. YoY

▲ +12.3%

Why it matters

Celltrion Pharm holds the exclusive domestic distribution rights for biologic medicines developed by its parent company, Celltrion, and distributes twelve such products in South Korea.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?